Rofecoxib

Research use only, not for human use.

A potent, selective and orally active COX-2 inhibitor with IC50 of 26 nM for inhibition of the COX-2-dependent production of PGE2 in human osteosarcoma cells.

A potent, selective and orally active COX-2 inhibitor with IC50 of 26 nM for inhibition of the COX-2-dependent production of PGE2 in human osteosarcoma cells; displays 1,000-fold selectivity over COX-1 activity; selectively inhibits LPS-induced, COX-2-derived PGE(2) synthesis after blood coagulation (IC50=0.53 uM); exhibits anti-inflammation activity in osteoarthritis and rheumatoid arthritis rodent models.Pain Withdrawn

MK-0996;MK-966

Chromatin/Epigenetic

COX

COX-2

Neurological Disease

Pain

162011-90-7

314.36

C17H14O4S

>98% (HPLC)

10 mM in DMSO

O=C1C(C2=CC=CC=C2)=C(C3=CC=C(S(=O)(C)=O)C=C3)CO1

2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-

(-20℃)

With Ice Pack

≥ 2 years